NEW YORK (GenomeWeb News) – Cowen & Co. today started covering Bruker, giving it an Outperform rating and a $21 price target.

In a research report, analyst Doug Schenkel said that while Bruker has challenges ahead and near-term catalysts for its shares are not obvious, "we are enthused about the long-term potential and associated unlocking of significant value; we view the risk/reward as very compelling for investors with an 18-24 month investment horizon."

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

In a statement, National Institutes of Health Director Francis Collins says sexual harassment is "morally indefensible" and "unacceptable."

Octopuses might owe their intelligence to their liberal alterations to their genes, Cosmos reports.

Stat News and ProPublica report that African Americans are underrepresented in cancer clinical trials.

In Cell this week: genomic analysis of abdominal aortic aneurysm, effect of probiotics on the microbiome, and more.

Oct
10
Sponsored by
Philips Genomics

This webinar will provide a first-hand look at how the Dana-Farber Cancer Center is adapting its oncology care strategy in light of the rapidly evolving molecular landscape.